BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
Open Access
- 1 July 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 7 (7), 1047-1053
- https://doi.org/10.1158/2326-6066.cir-18-0551
Abstract
We present a case of a patient with multiply relapsed, refractory myeloma whose clinical course showed evidence of a synergistic abscopal-like response to chimeric antigen receptor (CAR) T-cell therapy and localized radiotherapy (XRT). Shortly after receiving B-cell maturation antigen (BCMA)–targeted CAR T-cell therapy, the patient required urgent high-dose steroids and XRT for spinal cord compression. Despite the steroids, the patient had a durable systemic response that could not be attributed to XRT alone. Post-XRT findings included a second wave of fever and increased CRP and IL6, beginning 21 days after CAR T cells, which is late for cytokine-release syndrome from CAR T-cell therapy alone on this trial. Given this response, which resembled cytokine-release syndrome, immediately following XRT, we investigated changes in the patient's T-cell receptor (TCR) repertoire over 10 serial time points. Comparing T-cell diversity via Morisita's overlap indices (CD), we discovered that, although the diversity was initially stable after CAR T-cell therapy compared with baseline (CD = 0.89–0.97, baseline vs. 4 time points after CAR T cells), T-cell diversity changed after the conclusion of XRT, with >30% newly expanded TCRs (CD = 0.56–0.69, baseline vs. 4 time points after XRT). These findings suggest potential synergy between radiation and CAR T-cell therapies resulting in an abscopal-like response.Keywords
Other Versions
Funding Information
- NIH (R01 CA138738-05, P01 CA059350, and PO1 CA190174-01)
This publication has 20 references indexed in Scilit:
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJournal of Clinical Oncology, 2017
- Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancerBritish Journal of Cancer, 2016
- Erratum: The future of cancer treatment: immunomodulation, CARs and combination immunotherapyNature Reviews Clinical Oncology, 2016
- PD-1 Restrains Radiotherapy-Induced Abscopal EffectCancer Immunology Research, 2015
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?Cancer Immunology Research, 2014
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapyOncoImmunology, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung CancerCancer Immunology Research, 2013
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012